Seattle Genetics

SGEN NASDAQ
75.17
+11.99
+18.98%
After Hours: 75.00 -0.17 -0.23% 19:31 07/17 EDT
Open
69.89
Prev Close
63.18
High
76.07
Low
69.00
Volume
5.92M
Avg Vol (3M)
854.63K
52 Week High
84.37
52 Week Low
50.71
% Turnover
3.67%
Market Cap
12.13B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Seattle Genetics SGEN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
MORE >

Recently

Name
Price
%Change